Last reviewed · How we verify
NCT05194371
Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China
trial testing definitive radiotherapy or definitive chemoradiotherapy in Esophageal Neoplasms in 3,000 participants. Completed in 15 December 2021.
31 October 2021
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 June 2021 |
| Primary completion | 31 October 2021 |
| Estimated completion | 15 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- definitive radiotherapy or definitive chemoradiotherapy
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Sponsor
Chinese Academy of Medical Sciences — full company profile →
Who can join
18 and older, any sex, with Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, data of esophageal cancer patients undergoing definitive radiotherapy in 14 institutions from various provinces in China were evaluated to help strengthen confidence in anti-cancer, including rehabilitation, economic burden, and quality of life.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Quality of life and survival outcomes of patients with inoperable esophageal squamous cell carcinoma after definitive radiation therapy: A multicenter retrospective observational study in China from 2015 to 2016.
Wang X, Liang F, Wang X, Wu Y, et al · · 2023 · cited 14× · PMID 39035729 · DOI 10.1016/j.jncc.2023.05.001
Verify or expand the search:
- PubMed search for NCT05194371
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
- NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
- NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
- NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
- NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05194371 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
- Last refreshed: 18 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05194371.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing